These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27443691)

  • 21. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
    Gamucci T; Mentuccia L; Natoli C; Sperduti I; Cassano A; Michelotti A; Di Lauro L; Sergi D; Fabi A; Sarobba MG; Marchetti P; Barba M; Magnolfi E; Maugeri-Saccà M; Rossi E; Sini V; Grassadonia A; Pellegrini D; Astone A; Nisticò C; Angelini F; Vaccaro A; Pellegrino A; De Angelis C; Palleschi M; Moscetti L; Bertolini I; Buglioni S; Giordano A; Pizzuti L; Vici P
    J Cell Physiol; 2017 Jun; 232(6):1571-1578. PubMed ID: 27861874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
    Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
    Lang I; Inbar MJ; Kahán Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Messinger D; Brodowicz T; Zielinski C
    Eur J Cancer; 2012 Nov; 48(17):3140-9. PubMed ID: 22640829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
    Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
    Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.
    Pizzuti L; Sergi D; Sperduti I; Lauro LD; Mazzotta M; Botti C; Izzo F; Marchetti L; Tomao S; Marchetti P; Natoli C; Grassadonia A; Gamucci T; Mentuccia L; Magnolfi E; Vaccaro A; Cassano A; Rossi E; Botticelli A; Sini V; Sarobba MG; Fabbri MA; Moscetti L; Astone A; Michelotti A; De Angelis C; Bertolini I; Angelini F; Ciliberto G; Maugeri-Saccà M; Giordano A; Barba M; Vici P
    Cancer Biol Ther; 2018 Apr; 19(4):328-334. PubMed ID: 29336662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
    Yardley DA; Bosserman LD; O'Shaughnessy JA; Harwin WN; Morgan SK; Priego VM; Peacock NW; Bass JD; Burris HA; Hainsworth JD
    Breast Cancer Res Treat; 2015 Nov; 154(1):89-97. PubMed ID: 26456573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
    Welt A; Marschner N; Lerchenmueller C; Decker T; Steffens CC; Koehler A; Depenbusch R; Busies S; Hegewisch-Becker S
    Breast Cancer Res Treat; 2016 Feb; 156(1):97-107. PubMed ID: 26927446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).
    Hurvitz SA; Allen HJ; Moroose RL; Chan D; Hagenstad C; Applebaum SH; Patel G; Hu EH; Ryba N; Lin LS; Wang H; Glaspy J; Slamon DJ; Kabbinavar F
    Clin Breast Cancer; 2010 Aug; 10(4):307-12. PubMed ID: 20705564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
    Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
    J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
    Megerdichian C; Olimpiadi Y; Hurvitz SA
    Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.
    Schwartzberg LS; Badarinath S; Keaton MR; Childs BH
    Clin Breast Cancer; 2014 Jun; 14(3):161-8. PubMed ID: 24566467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study.
    Xu BH; Jiang ZF; Shen ZZ; Guan ZZ; Chen ZD; Cheng Y; Zheng H; Jiang J; Wang XJ; Tong ZS; Qin SK; Luo Y; Yao M; Wang LW; He J
    Chin Med J (Engl); 2012 Mar; 125(5):764-9. PubMed ID: 22490570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
    Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
    Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of bevacizumab in combination with paclitaxel for metastatic breast cancer].
    Suzuki S; Sakurai K; Nagashima S; Hara Y; Amano S; Enomoto K; Makishima M
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1289-91. PubMed ID: 25335720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acral cutaneous metastasis from a primary breast carcinoma following chemotherapy with bevacizumab and paclitaxel.
    Armstrong P; Woody MM; Reichenberg JS; Gavino AC
    Cutis; 2018 Sep; 102(3):E12-E14. PubMed ID: 30372726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study.
    Dank M; Budi L; Piko B; Mangel L; Erfan J; Cseh J; Ruzsa A; Landherr L
    Anticancer Res; 2014 Mar; 34(3):1275-80. PubMed ID: 24596372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
    Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
    Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Usefulness of bevacizumab combination chemotherapy for advanced breast cancer].
    Aomatsu N; Kashiwagi S; Morisaki T; Ishihara S; Asano Y; Watanabe M; Noda S; Kawajiri H; Takashima T; Onoda N; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2393-5. PubMed ID: 24394123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies.
    Yamamoto Y; Yamashiro H; Schneeweiss A; Müller V; Gluz O; Klare P; Aktas B; Magdolna D; Büdi L; Pikó B; Mangel L; Toi M; Morita S; Ohno S
    Breast Cancer; 2023 Jan; 30(1):88-100. PubMed ID: 36057014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.